Skip to content
10-Q

Quarterly Report

ANIXA BIOSCIENCES, INC. ANIX

0001493152-23-031826

← back to feed
Filed
Sep 6, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2023 · Sep 6, 2023 31.07M sh
Short Term Investments Q3 2023 · Jul 31, 2023 $22.34M
Short Term Investments Q3 2023 · Oct 31, 2022 $17.33M
Cash And Equivalents Q3 2023 · Jul 31, 2023 $3.2M
Cash And Equivalents Q3 2023 · Oct 31, 2022 $12.36M
Stockholders Equity Q3 2023 · Jul 31, 2023 $25.52M
Stockholders Equity Q3 2023 · Oct 31, 2022 $29.05M
Current Liabilities Q3 2023 · Jul 31, 2023 $1.86M
Current Liabilities Q3 2023 · Oct 31, 2022 $2.04M
Total Liabilities Q3 2023 · Jul 31, 2023 $1.99M
Total Liabilities Q3 2023 · Oct 31, 2022 $2.21M
Current Assets Q3 2023 · Jul 31, 2023 $26.4M
Current Assets Q3 2023 · Oct 31, 2022 $30.2M
Total Assets Q3 2023 · Jul 31, 2023 $26.58M
Total Assets Q3 2023 · Oct 31, 2022 $30.41M
Shares Diluted Q3 2023 · Jul 31, 2022 30.45K sh
Shares Diluted Q3 2023 · Jul 31, 2022 30.24K sh
Operating Cash Flow Q3 2023 · Jul 31, 2022 −$4.9M
Eps Diluted Q3 2023 · Jul 31, 2022 −$0.09
Eps Diluted Q3 2023 · Jul 31, 2022 −$0.33
Eps Basic Q3 2023 · Jul 31, 2022 −$0.09
Eps Basic Q3 2023 · Jul 31, 2022 −$0.33
Rd Expense Q3 2023 · Jul 31, 2022 $1.45M
Rd Expense Q3 2023 · Jul 31, 2022 $5.02M
Net Income Q3 2023 · Jul 31, 2022 −$2.75M
Net Income Q3 2023 · Jul 31, 2022 −$10.12M
Operating Income Q3 2023 · Jul 31, 2022 −$2.8M
Operating Income Q3 2023 · Jul 31, 2022 −$10.27M